Literature DB >> 6487823

Thymidine kinase as a predictor of response to chemotherapy in advanced breast cancer.

H J Zhang, B J Kennedy, D T Kiang.   

Abstract

Cytosols from breast cancers were measured for estrogen receptor (ER) and thymidine kinase (TK) activity. There was no correlation between ER and TK in 137 primary breast cancers studied. The results of TK from 57 metastatic breast cancers were correlated with the response or failure to subsequent hormonal therapy or chemotherapy. TK did not predict the responses to hormonal therapy in 12 patients. Of the 45 patients treated with chemotherapies, 13 of 15 tumors with TK over 80 pmol/mg/min responded (86%), while only 4 of the 30 tumors (13%) with TK below 80 pmol/mg/min responded (p less than 0.001). TK appears to be useful in predicting the responses to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6487823     DOI: 10.1007/bf01806488

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  14 in total

1.  The feedback inhibition of thymidine kinase.

Authors:  T R BREITMAN
Journal:  Biochim Biophys Acta       Date:  1963-01-08

2.  Proliferative parameters relevant to cancer therapy.

Authors:  M F Rajewsky
Journal:  Recent Results Cancer Res       Date:  1975

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland.

Authors:  J L Hayward; P P Carbone; J C Heuson; S Kumaoka; A Segaloff; R D Rubens
Journal:  Cancer       Date:  1977-03       Impact factor: 6.860

5.  Thymidine kinase, DNA synthesis and cancer.

Authors:  S Kit
Journal:  Mol Cell Biochem       Date:  1976-06-15       Impact factor: 3.396

Review 6.  Proliferation-dependent cytotoxicity of anticancer agents: a review.

Authors:  F Valeriote; L van Putten
Journal:  Cancer Res       Date:  1975-10       Impact factor: 12.701

7.  Purification and properties of estrogen-responsive cytoplasmic thymidine kinase from human breast cancer.

Authors:  D A Bronzert; M E Monaco; L Pinkus; S Aitken; M E Lippman
Journal:  Cancer Res       Date:  1981-02       Impact factor: 12.701

8.  The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer.

Authors:  M E Lippman; J C Allegra; E B Thompson; R Simon; A Barlock; L Green; K K Huff; H M Do; S C Aitken; R Warren
Journal:  N Engl J Med       Date:  1978-06-01       Impact factor: 91.245

9.  Evaluation of estrogen receptor assays in human breast cancer tissue.

Authors:  W L McGuire; M De La Garza; G C Chamness
Journal:  Cancer Res       Date:  1977-03       Impact factor: 12.701

10.  Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer.

Authors:  D T Kiang; D H Frenning; A I Goldman; V F Ascensao; B J Kennedy
Journal:  N Engl J Med       Date:  1978-12-14       Impact factor: 91.245

View more
  3 in total

1.  Predicting chemosensitivity of tumors.

Authors:  J Mattern; K Wayss; M Volm
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

2.  Neuron specific enolase (NSE) and thymidine kinase (TK) as markers in biological fluids of brain tumor patients.

Authors:  A Boiardi; L Munari; A Silvani; C L Solero; E Bombardieri
Journal:  Ital J Neurol Sci       Date:  1990-08

3.  Methylsulfonylmethane suppresses breast cancer growth by down-regulating STAT3 and STAT5b pathways.

Authors:  Eun Joung Lim; Dae Young Hong; Jin Hee Park; Youn Hee Joung; Pramod Darvin; Sang Yoon Kim; Yoon Mi Na; Tae Sook Hwang; Sang-Kyu Ye; Eon-Soo Moon; Byung Wook Cho; Kyung Do Park; Hak Kyo Lee; Taekyu Park; Young Mok Yang
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.